Nanna Therapeutics
Ewan Marks is a Research Associate II at Astellas Pharma since January 2022, previously gaining experience as a Research Placement at the University of Oxford from September 2019 to May 2020. Ewan holds a Bachelor of Science degree in Biological Sciences from the University of Birmingham, where studies were completed from 2017 to 2021. Earlier education was completed at The South Wolds Academy & Sixth Form between 2010 and 2017.
Nanna Therapeutics
Nanna Therapeutics is a drug discovery company addressing age-related diseases for which others are failing to provide effective treatments. These include mitochondrial, neurodegenerative, cardiovascular or metabolic, joint or tissue disease as well as cancer.Nanna Therapeutics are targeting fundamental cellular processes to create drugs to treatage-related diseases and improve longevity. Such drugs include those to combat debilitating neurodegenerative, inflammatory, cardiovascular and metabolic diseases as well as many cancers. With a strong focus on mitochondria, the energy source in every cell, we can target the fundamental causes of many age-related diseases. Through this approach we can also address debilitating, life-limiting mitochondrial diseases for which there are currently few effective therapies.Nanna Therapeutics has developed a tightly integrated set of proprietary technologies that radically disrupt current methods of creating new medicines. This Totally Integrated Medicines Engine (TIME) has been devised to answer the needs of drug discovery and development scientists utilising the best in 21st century technologies of microfluidics, nanofabrication and artificial intelligence.